Objective: To investigate the mechanism underlying the development of chronic hepatitis B virus infection (HBV) in Turkish population using HLA tissue typing.
Methods: The study group I consisted of 20 patients with HBV-related chronic liver disease (cirrhosis, chronic active hepatitis or chronic persistent hepatitis). The study group II included 30 HBV chronic carriers. The control group consisted of 50 healthy subjects with negative serologic markers for HBV. HLA typing was performed by Terasaki's microlymphocytotoxicity method.
Results: The frequencies of HLA-DR13 and DQ3 were significantly higher in the patients with HBV-related chronic liver disease compared to those of control group. The absence of HLA-A24 and CW1 was also significant in group I. The frequencies of HLA A2, B8, B13, CW3, DR13 were significantly higher in group II compared to the control group. There were increased frequencies of HLA- B8, B13, DR7, DR13, and DQ3 in both group I and group II.
Conclusion: HLA-A24 AND Cw1 were associated with low risk for HBV-related chronic liver disease and HLA- B13, B8, DR7, DR13 and DQ3 were associated with high risk for chronic HBV infection in the Turkish population (JPMA 52:253;2002).
Download full-text PDF |
Source |
---|
Viruses
December 2024
Department of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
This study aimed to investigate the impact of IL-35 on the prognosis of patients with HBV-ACLF. We recruited 69 patients with HBV-ACLF, 20 patients with chronic hepatitis B (CHB), 17 patients with liver cirrhosis (LC), and 20 healthy controls (HCs) from a regional infectious disease treatment center in China. Plasma levels of IL-35 at baseline were detected using ELISA.
View Article and Find Full Text PDFInt Immunopharmacol
January 2025
Department of Transplantation Immunology, Institute of Translational Medicine, The First Hospital of Jilin University, Changchun, Jilin Province 130061, China. Electronic address:
Chronic hepatitis B virus (HBV) infection is a major risk factor for liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Despite advances in understanding HBV-related liver diseases, effective therapeutic strategies remain limited. Macrophage migration inhibitory factor (MIF) has been implicated in various inflammatory and fibrotic conditions, but its role in HBV-induced liver fibrosis has not been fully explored.
View Article and Find Full Text PDFFront Microbiol
December 2024
Clinical Medical Research Center, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, Guangdong, China.
Introduction: Liver cirrhosis (LC) and hepatocellular carcinoma (HCC) resulting from chronic hepatitis B virus (HBV) infection are major health concerns. Identifying critical biomarkers and molecular targets is needed for early diagnosis, prognosis, and therapy of these diseases.
Methods: In this study, we explored the gene expression and metabolism in the liver tissues of LC, HCC, and healthy controls, to analyse and identify potential biomarkers of disease progression.
J Natl Compr Canc Netw
December 2024
1Department of Hepatology, The Fifth People's Hospital of Ganzhou, Ganzhou, Jiangxi Province, China.
Purpose: More than 60% of patients with hepatocellular carcinoma (HCC) do not receive curative therapeutics due to late clinical manifestations and diagnosis. The 5-year survival rate for advanced HCC is approximately 2%. However, curative therapies for HCC detected early can improve the 5-year survival rate to >70%.
View Article and Find Full Text PDFGastroenterol Res Pract
December 2024
Clinical Medical Research Center, The Fifth People's Hospital of Wuxi, Wuxi, China.
The prognosis of patients with liver failure (LF) depends significantly on the etiology and clinical indicators. This analysis of these basic indicators can help provide a basis for the study of predictive outcome indicators. We collected the data from multiple centers in Southeast China, including subclasses of acute liver failure (ALF), subacute liver failure (SLF), acute-on-chronic liver failure (ACLF), subacute-on-chronic liver failure (SALF), and chronic liver failure (CLF).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!